Kairos Pharma (KAPA) shares were down 14% in recent Tuesday trading after the company said it received approval to dual list its stock on Upstream, a global trading app for digital securities.
With the dual listing, the company said it can access a global investor base outside the US for additional liquidity and price discovery enhancement.
The Upstream platform facilitates real-time trading and settlement, and ensures a transparent orderbook that does not allow common market manipulations, Kairos said.
Price: 1.43, Change: -0.28, Percent Change: -16.37
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.